# Management Review Minutes
## MedFlow V3 Clinical Decision Support System

**Document ID:** MF-ISO42001-MRM-001
**Version:** 1.0
**Classification:** Internal
**Last Updated:** 2026-02-09
**Author:** Dr. Islam Mekawy, Lead Implementer
**ISO 42001 Reference:** Clause 9.3 - Management Review

---

## 1. Purpose

This document records the management review of the MedFlow V3 AI Management System (AIMS) conducted in accordance with ISO 42001:2023 Clause 9.3. Management reviews ensure the continued suitability, adequacy, and effectiveness of the AIMS and identify opportunities for improvement.

---

## 2. Review Schedule

| Review Cycle | Date | Type | Status |
|--------------|------|------|--------|
| Q1 2026 (Initial) | 2026-02-09 | Comprehensive | COMPLETED |
| Q2 2026 | 2026-05-15 | Periodic | SCHEDULED |
| Q3 2026 | 2026-08-15 | Periodic | PLANNED |
| Q4 2026 | 2026-11-15 | Annual | PLANNED |

---

## 3. Review Meeting #1 - February 9, 2026

### 3.1 Meeting Details

| Attribute | Detail |
|-----------|--------|
| **Date** | February 9, 2026 |
| **Time** | 10:00 - 11:30 AST (Arabia Standard Time) |
| **Location** | Remote (Personal Research Initiative) |
| **Type** | Q1 Comprehensive Review |
| **Duration** | 90 minutes |

### 3.2 Attendees

| Role | Name | Responsibility |
|------|------|----------------|
| Lead Implementer / Principal Investigator | Dr. Islam Mekawy | AIMS owner, technical lead, audit authority |

---

## 4. Review Inputs

### 4.1 AIMS Performance Summary

| Metric | Value | Assessment |
|--------|-------|------------|
| **Development Phases Completed** | 5 of 6 (Phase 6 Active) | On track |
| **Build Sessions Completed** | 10 | Documented in Project Tracker |
| **Professional Hours Logged** | 64 hours | Per Implementation Experience Log |
| **Core Modules Operational** | 5/5 | All functional |
| **ISO Controls Mapped** | 39/39 | 92% conformant (per Internal Audit) |
| **Test Pass Rate** | 100% | DRG 8/8, KB 6/6, Dashboard 5/5 |
| **MOH Protocols Loaded** | 13 | Knowledge Base operational |
| **Saved Case Analyses** | 5+ | All render correctly in dashboard |

### 4.2 Status of Actions from Previous Reviews

This is the initial management review; no prior actions exist.

### 4.3 Internal Audit Results

Reference: `iso42001-artifacts/Internal_Audit_Report.md` (MF-ISO42001-IAR-001)

| Finding | Clause | Severity | Status |
|---------|--------|----------|--------|
| NC-001: Competence Assessment Records | 7.2 | Minor | OPEN - Target 2026-03-15 |
| NC-002: Fairness Validation Not Executed | 8.2 | Minor | OPEN - Target 2026-04-30 |
| NC-003: Automated Drift Detection | Annex A | Minor | OPEN - Target 2026-05-31 |
| OBS-001: Protocol Coverage Gaps | KB | Observation | NOTED |
| OBS-002: PII Performance Benchmarks | PII | Observation | NOTED |
| OBS-003: Terminology Standardization | Phase 5.5 | Observation | NOTED |

### 4.4 Risk Register Review

Reference: `iso42001-artifacts/AI_Risk_Register.md` (v3.0, 14 risks)

| Risk Category | Count | High | Medium | Low |
|---------------|-------|------|--------|-----|
| Technical | 8 | 2 | 4 | 2 |
| Strategic/Governance | 6 | 1 | 3 | 2 |
| **Total** | **14** | **3** | **7** | **4** |

**High-Priority Risks Reviewed:**
1. **RISK-001: PII Leakage** - Mitigated by Defense in Depth (Regex + LLM + Validation). Residual risk: Low.
2. **RISK-003: Gemini Hallucination** - Mitigated by Knowledge Base hierarchy and General Clinical Fallback. Residual risk: Medium.
3. **RISK-009: Regulatory Non-compliance** - Mitigated by PDPL alignment in AI Data Policy. Residual risk: Medium (NPHIES integration pending).

### 4.5 Interested Party Feedback

| Stakeholder | Feedback Channel | Key Input |
|-------------|-----------------|-----------|
| Clinical Users | Not yet deployed | Dashboard design reviewed internally |
| Regulatory Bodies | Standards review | ISO 42001 + PDPL requirements incorporated |
| Development Team | Session logs | Iterative improvements across 10 sessions |

---

## 5. Review Discussion and Analysis

### 5.1 AIMS Effectiveness Assessment

**Overall Assessment: EFFECTIVE with identified improvement areas.**

The AIMS has progressed from concept (Phase 1) to a functional prototype (Phase 5) with ISO governance framework (Phase 6) in 10 build sessions over 9 days. Key effectiveness indicators:

- **Clinical Pipeline**: Six-layer architecture processes cases end-to-end with PII protection, clinical analysis, guideline enforcement, DRG validation, and dashboard rendering.
- **Self-Healing**: Gemini client auto-fallback demonstrated during production use (429 errors resolved automatically).
- **Traceability**: Every case produces auditable output with PII manifest, processing metadata, and guideline citations.
- **Governance**: 39 ISO 42001 controls mapped with 92% conformance.

### 5.2 Resource Adequacy

| Resource | Status | Assessment |
|----------|--------|------------|
| **Compute (Local)** | Ollama + Llama 3.2 (32GB RAM) | Adequate for PII scrubbing |
| **Compute (Cloud)** | Gemini 2.0/2.5 Flash (API key) | Adequate; quota limits managed by auto-fallback |
| **Knowledge Base** | 13 MOH Protocol PDFs | Adequate for MVP; gaps in ACS/Stroke/Sepsis |
| **Development Environment** | Python 3.12 + venv + Streamlit | Adequate |
| **Documentation** | 13+ ISO artifacts | Exceeds initial 10-document target |
| **Personnel** | Single researcher | Sufficient for research prototype; production would require team |

### 5.3 Opportunities for Improvement

Identified during this review:

1. **Production Readiness**: System is research-grade; production deployment requires additional security hardening, load testing, and multi-user support.
2. **Protocol Expansion**: Add missing clinical protocols (ACS/STEMI, Stroke, Sepsis) to improve citation specificity.
3. **Performance Benchmarking**: Formal before/after measurements for PII scrubber optimization.
4. **Regulatory Package**: PDPL/NPHIES compliance study package (0/6 documents) is the next major deliverable.

---

## 6. Key Decisions

| Decision ID | Decision | Rationale | Owner | Date |
|-------------|----------|-----------|-------|------|
| MRD-001 | Accept 3 minor non-conformances with corrective action plan | All are evidence gaps, not fundamental failures; acceptable for research prototype | Dr. Islam Mekawy | 2026-02-09 |
| MRD-002 | Proceed with Phase 6 completion before starting Regulatory Package | ISO evidence generation is near-complete (3 remaining docs); finish before context-switching | Dr. Islam Mekawy | 2026-02-09 |
| MRD-003 | Defer production deployment planning to Q2 2026 | Current focus is research deliverables and ISO certification pathway | Dr. Islam Mekawy | 2026-02-09 |
| MRD-004 | Maintain current Gemini 2.0/2.5 Flash models | API key constraints; no business need to change | Dr. Islam Mekawy | 2026-02-09 |
| MRD-005 | Schedule Q2 review for May 15, 2026 | Allows time for NC corrective actions and Regulatory Package progress | Dr. Islam Mekawy | 2026-02-09 |

---

## 7. Action Items

| Action ID | Action | Owner | Due Date | Priority | Status |
|-----------|--------|-------|----------|----------|--------|
| MRA-001 | Create competence assessment matrix (NC-001) | Dr. Islam Mekawy | 2026-03-15 | High | OPEN |
| MRA-002 | Design and execute fairness test suite (NC-002) | Dr. Islam Mekawy | 2026-04-30 | High | OPEN |
| MRA-003 | Implement automated drift detection (NC-003) | Dr. Islam Mekawy | 2026-05-31 | Medium | OPEN |
| MRA-004 | Add ACS/Stroke/Sepsis protocols to KB (OBS-001) | Dr. Islam Mekawy | 2026-03-31 | Medium | OPEN |
| MRA-005 | Run PII scrubber performance benchmark (OBS-002) | Dr. Islam Mekawy | 2026-03-15 | Low | OPEN |
| MRA-006 | Start Regulatory Package (PDPL/NPHIES) | Dr. Islam Mekawy | 2026-04-15 | Medium | OPEN |

---

## 8. Next Review

| Attribute | Detail |
|-----------|--------|
| **Next Review Date** | May 15, 2026 |
| **Review Type** | Q2 Periodic Review |
| **Key Agenda Items** | NC corrective action verification, Regulatory Package progress, Q1 action item closeout |
| **Preparation Required** | Updated Risk Register, NC closure evidence, performance benchmark results |

---

## Document Approval

| Role | Name | Date | Signature |
|------|------|------|-----------|
| Management Representative | Dr. Islam Mekawy | 2026-02-09 | __________ |
| Lead Implementer | Dr. Islam Mekawy | 2026-02-09 | __________ |

---

## Revision History

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0 | 2026-02-09 | Dr. Islam Mekawy | Initial management review (Q1 2026) |

---

*End of Document*
